Richard Nolan Townsend Sells 3,345 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 3,345 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $4.95, for a total transaction of $16,557.75. Following the transaction, the chief executive officer owned 374,472 shares in the company, valued at approximately $1,853,636.40. The trade was a 0.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Wednesday, July 1st, Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56.

Lexeo Therapeutics Trading Up 8.9%

Shares of LXEO traded up $0.44 during midday trading on Wednesday, reaching $5.37. The stock had a trading volume of 941,872 shares, compared to its average volume of 952,662. The firm has a market cap of $440.61 million, a PE ratio of -4.67 and a beta of 1.46. The firm has a 50 day simple moving average of $4.70 and a 200-day simple moving average of $5.56. Lexeo Therapeutics, Inc. has a one year low of $3.99 and a one year high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.01). As a group, research analysts forecast that Lexeo Therapeutics, Inc. will post -1.18 EPS for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new stake in Lexeo Therapeutics in the 2nd quarter valued at $32,000. Allworth Financial LP increased its position in Lexeo Therapeutics by 1,002.9% during the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after buying an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after buying an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at about $37,000. Finally, California State Teachers Retirement System boosted its position in shares of Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after acquiring an additional 2,148 shares during the period. 60.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LXEO has been the subject of several research analyst reports. Wall Street Zen downgraded Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. reduced their price objective on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. Finally, Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $18.75.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.